Journal of Movement Disorders

Letter to the editor

Deep Brain Stimulation in Advanced Parkinson’s Disease: An Uncommon Case of Allergic Encephalitis: Jyun-Yi Chen, Yen-Chung Chen, Shey-Lin Wu; Received November 16, 2023 Accepted April 12, 2024 Published online April 15, 2024; DOI: https://doi.org/10.14802/jmd.23237 [Accepted]

404 View
10 Download

PDF

Review Article

Multiple System Atrophy: Advances in Diagnosis and Therapy: Hirohisa Watanabe, Sayuri Shima, Yasuaki Mizutani, Akihiro Ueda, Mizuki Ito; J Mov Disord. 2023;16(1):13-21. Published online December 20, 2022; DOI: https://doi.org/10.14802/jmd.22082

3,795 View
422 Download
2 Web of Science
2 Crossref

This review summarizes improvements in understanding the pathophysiology and early clinical symptoms of multiple system atrophy (MSA) and advancements in diagnostic methods and disease-modifying therapies for the condition. In 2022, the Movement Disorder Society proposed new diagnostic criteria to develop disease-modifying therapies and promote clinical trials of MSA since the second consensus was proposed in 2008. Regarding pathogenesis, cutting-edge findings have accumulated on the interactions of α-synuclein, neuroinflammation, and oligodendroglia with neurons. In neuroimaging, introducing artificial intelligence, machine learning, and deep learning has notably improved diagnostic accuracy and individual analyses. Advancements in treatment have also been achieved, including immunotherapy therapy against α-synuclein and serotonin-targeted and mesenchymal stem cell therapies, which are thought to affect several aspects of the disease, including neuroinflammation. The accelerated progress in clarifying the pathogenesis of MSA over the past few years and the development of diagnostic techniques for detecting early-stage MSA are expected to facilitate the development of disease-modifying therapies for one of the most intractable neurodegenerative diseases.

Citations

Citations to this article as recorded by

A Blinded Evaluation of Brain Morphometry for Differential Diagnosis of Atypical Parkinsonism
Kazuya Kawabata, Florian Krismer, Beatrice Heim, Anna Hussl, Christoph Mueller, Christoph Scherfler, Elke R. Gizewski, Klaus Seppi, Werner Poewe
Movement Disorders Clinical Practice.2024; 11(4): 381. CrossRef
The potential of phosphorylated α‐synuclein as a biomarker for the diagnosis and monitoring of multiple system atrophy
Toufik Abdul‐Rahman, Ranferi Eduardo Herrera‐Calderón, Arjun Ahluwalia, Andrew Awuah Wireko, Tomas Ferreira, Joecelyn Kirani Tan, Maximillian Wolfson, Shankhaneel Ghosh, Viktoriia Horbas, Vandana Garg, Asma Perveen, Marios Papadakis, Ghulam Md Ashraf, Ath
CNS Neuroscience & Therapeutics.2024;[Epub] CrossRef

Original Articles

Fecal Calprotectin in Parkinson’s Disease and Multiple System Atrophy: Jia Wei Hor, Shen-Yang Lim, Eng Soon Khor, Kah Kian Chong, Sze Looi Song, Norlinah Mohamed Ibrahim, Cindy Shuan Ju Teh, Chun Wie Chong, Ida Normiha Hilmi, Ai Huey Tan; J Mov Disord. 2022;15(2):106-114. Published online December 24, 2021; DOI: https://doi.org/10.14802/jmd.21085

5,550 View
345 Download
11 Web of Science
12 Crossref

Abstract PDF Supplementary Material

Objective
Converging evidence suggests that intestinal inflammation is involved in the pathogenesis of neurodegenerative diseases. Previous studies on fecal calprotectin in Parkinson’s disease (PD) were limited by small sample sizes, and literature regarding intestinal inflammation in multiple system atrophy (MSA) is very scarce. We investigated the levels of fecal calprotectin, a marker of intestinal inflammation, in PD and MSA.
Methods
We recruited 169 subjects (71 PD, 38 MSA, and 60 age-similar nonneurological controls). Clinico-demographic data were collected. PD and MSA were subtyped and the severity assessed using the MDS-UPDRS and UMSARS, respectively. Fecal calprotectin and blood immune markers were analyzed.
Results
Compared to controls (median: 35.7 [IQR: 114.2] μg/g), fecal calprotectin was significantly elevated in PD (median: 95.6 [IQR: 162.1] μg/g, p = 0.003) and even higher in MSA (median: 129.5 [IQR: 373.8] μg/g, p = 0.002). A significant interaction effect with age was observed; between-group differences were significant only in older subjects (i.e., ≥ 61 years) and became more apparent with increasing age. A total of 28.9% of MSA and 18.3% of PD patients had highly abnormal fecal calprotectin levels (≥ 250 μg/g); however, this difference was only significant for MSA compared to controls. Fecal calprotectin correlated moderately with selected blood immune markers in PD, but not with clinical features of PD or MSA.
Conclusions
Elevated fecal calprotectin suggests a role for intestinal inflammation in PD and MSA. A more complete understanding of gut immune alterations could open up new avenues of research and treatment for these debilitating diseases.

Citations

Citations to this article as recorded by

Calprotectin in Parkinsonian disease: Anticipation and dedication
Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Ayah Talal Zaidalkiani, Athanasios Alexiou, Marios Papadakis, Mostafa M. Bahaa, Ammar AL-Faraga, Gaber El-Saber Batiha
Ageing Research Reviews.2024; 93: 102143. CrossRef
Diagnostic Accuracy of Fecal Calprotectin in Discriminating Organic-Inflammatory Gastrointestinal Diseases and Functional Gastrointestinal Disorders in Older Patients
Antonella Gallo, Marcello Covino, Silvia Baroni, Sara Camilli, Francesca Ibba, Silvia Andaloro, Maria Chiara Agnitelli, Fiammetta Maria Rognoni, Francesco Landi, Massimo Montalto
Journal of Personalized Medicine.2024; 14(3): 227. CrossRef
Nocardia cyriacigeorgica Elicits Gut Disturbances in a Leaky Gut Model of Colitis, but Not the Harmful Cascade Leading to Gut-First Parkinson’s Disease
João Duarte Magalhães, Emanuel Candeias, Inês Melo-Marques, António E. Abreu, Ana Raquel Pereira-Santos, Ana Raquel Esteves, Sandra Morais Cardoso, Nuno Empadinhas
International Journal of Molecular Sciences.2024; 25(6): 3423. CrossRef
Inflammation in multiple system atrophy
Marta Leńska-Mieciek, Natalia Madetko-Alster, Piotr Alster, Leszek Królicki, Urszula Fiszer, Dariusz Koziorowski
Frontiers in Immunology.2023;[Epub] CrossRef
Gut-to-brain spreading of pathology in synucleinopathies: A focus on molecular signalling mediators
Verena Schmitt, Rebecca Katharina Masanetz, Martin Weidenfeller, Lara Savannah Ebbinghaus, Patrick Süß, Stephan P. Rosshart, Stephan von Hörsten, Friederike Zunke, Jürgen Winkler, Wei Xiang
Behavioural Brain Research.2023; 452: 114574. CrossRef
Calprotectin, Biomarker of Depression in Patients with Inflammatory Bowel Disease?
Miorita Melina Iordache, Anca Mihaela Belu, Sabina E. Vlad, Kamer Ainur Aivaz, Andrei Dumitru, Cristina Tocia, Eugen Dumitru
Medicina.2023; 59(7): 1240. CrossRef
Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson’s disease
Amica C. Müller-Nedebock, Marieke C. J. Dekker, Matthew J. Farrer, Nobutaka Hattori, Shen-Yang Lim, George D. Mellick, Irena Rektorová, Mohamed Salama, Artur F. S. Schuh, A. Jon Stoessl, Carolyn M. Sue, Ai Huey Tan, Rene L. Vidal, Christine Klein, Soraya
npj Parkinson's Disease.2023;[Epub] CrossRef
Fecal calprotectin as an intestinal inflammation marker is elevated in glaucoma
Zuo Wang, Hang Yuan, Xiong Zhu, Jinxia Wang, Wenbo Xiu, Yang Chen, Gao Zhang, Jing Fu, Kun Peng, An Li, Donghua Liu, Xijing Huang, Chong He, Fang Lu
Biomarkers in Medicine.2023; 17(9): 465. CrossRef
Pesticides and the Microbiome-Gut-Brain Axis: Convergent Pathways in the Pathogenesis of Parkinson’s Disease
Kristina Kulcsarova, Corinna Bang, Daniela Berg, Eva Schaeffer
Journal of Parkinson's Disease.2023; 13(7): 1079. CrossRef
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic
Ai Huey Tan, Shen Yang Lim, Anthony E. Lang
Nature Reviews Neurology.2022; 18(8): 476. CrossRef
The Gut Microbiome–Brain Crosstalk in Neurodegenerative Diseases
Laura Ghezzi, Claudia Cantoni, Emanuela Rotondo, Daniela Galimberti
Biomedicines.2022; 10(7): 1486. CrossRef
Gastrointestinal Involvement in Extra-Digestive Disease: Which Is the Role of Fecal Calprotectin?
Angela Saviano, Marcello Candelli, Christian Zanza, Andrea Piccioni, Alessio Migneco, Veronica Ojetti
Medicina.2022; 58(10): 1384. CrossRef

Association of AXIN1 With Parkinson’s Disease in a Taiwanese Population: Hwa-Shin Fang, Chih-Ying Chao, Chun-Chieh Wang, Wen-Lang Fan, Po-Jung Huang, Hon-Chung Fung, Yih-Ru Wu; J Mov Disord. 2022;15(1):33-37. Published online November 17, 2021; DOI: https://doi.org/10.14802/jmd.21073

4,713 View
269 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material

Objective
A meta-analysis of locus-based genome-wide association studies recently identified a relationship between AXIN1 and Parkinson’s disease (PD). Few studies of Asian populations, however, have reported such a genetic association. The influences of rs13337493, rs758033, and rs2361988, three PD-associated genetic variants of AXIN1, were investigated in the present study because AXIN1 is related to Wnt/β-catenin signaling.
Methods
A total of 2,418 individuals were enrolled in our Taiwanese cohort for analysis of the genotypic and allelic frequency. Polymerase chain reaction–restriction fragment length polymorphism analysis was employed for rs13337493 genotyping, and the Agena MassARRAY platform (Agena Bioscience, San Diego, CA, USA) was used for rs758033 and rs2361988 genotyping in 672 patients with PD and 392 controls. Taiwan Biobank data of another 1,354 healthy controls were subjected to whole-genome sequencing performed using Illumina platforms at approximately 30× average depth.
Results
Our results revealed that rs758033 {odds ratios [OR] (95% confidence interval [CI]) = 0.267 [0.064, 0.795], p = 0.014} was associated with the risk of PD, and there was a trend toward a protective effect of rs2361988 (OR [95% CI] = 0.296 [0.071, 0.884], p = 0.026) under the recessive model. The TT genotype of rs758033 (OR [95% CI] = 0.271 [0.065, 0.805], p = 0.015) and the CC genotype of rs2361988 (OR [95% CI] = 0.305 [0.073, 0.913], p = 0.031) were less common in the PD group than in the non-PD group.
Conclusion
Our findings indicate that the rs758033 and rs2361988 polymorphisms of AXIN1 may affect the risk of PD in the Taiwanese population.

Citations

Citations to this article as recorded by

Disrupted epithelial permeability as a predictor of severe COVID‐19 development
Duygu Yazici, Eren Cagan, Ge Tan, Manru Li, Evan Do, Ozan C. Kucukkase, Abdurrahman Simsek, Muhammed Ali Kizmaz, Tugce Bozkurt, Tamer Aydin, Anja Heider, Beate Rückert, Marie‐Charlotte Brüggen, Raja Dhir, Liam O'Mahony, Mubeccel Akdis, Kari C. Nadeau, Fer
Allergy.2023; 78(10): 2644. CrossRef

Review Articles

Evidence of Inflammation in Parkinson’s Disease and Its Contribution to Synucleinopathy: Thuy Thi Lai, Yun Joong Kim, Hyeo-il Ma, Young Eun Kim; J Mov Disord. 2022;15(1):1-14. Published online November 3, 2021; DOI: https://doi.org/10.14802/jmd.21078

6,973 View
535 Download
12 Web of Science
12 Crossref

Abstract PDF

Accumulation of alpha-synuclein (αSyn) protein in neurons is a renowned pathological hallmark of Parkinson’s disease (PD). In addition, accumulating evidence indicates that activated inflammatory responses are involved in the pathogenesis of PD. Thus, achieving a better understanding of the interaction between inflammation and synucleinopathy in relation to the PD process will facilitate the development of promising disease-modifying therapies. In this review, the evidence of inflammation in PD is discussed, and human, animal, and laboratory studies relevant to the relationship between inflammation and αSyn are explored as well as new therapeutic targets associated with this relationship.

Citations

Citations to this article as recorded by

Recent advances of nanomaterials for intervention in Parkinson’s disease in the context of anti-inflammation
Ruoyu Zhang, Xiaotong Chen, Yuanyuan Cheng, Zixuan Chen, Xiaoqiong Li, Yulin Deng
Coordination Chemistry Reviews.2024; 502: 215616. CrossRef
Microglial inhibition alleviates alpha-synuclein propagation and neurodegeneration in Parkinson’s disease mouse model
Thuy Thi Lai, Young Eun Kim, Linh Thi Nhat Nguyen, Tinh Thi Nguyen, In Hee Kwak, Franziska Richter, Yun Joong Kim, Hyeo-il Ma
npj Parkinson's Disease.2024;[Epub] CrossRef
New Insights into Oxidative Stress and Inflammatory Response in Neurodegenerative Diseases
Eveljn Scarian, Camilla Viola, Francesca Dragoni, Rosalinda Di Gerlando, Bartolo Rizzo, Luca Diamanti, Stella Gagliardi, Matteo Bordoni, Orietta Pansarasa
International Journal of Molecular Sciences.2024; 25(5): 2698. CrossRef
Neuroinflammation following anti-parkinsonian drugs in early Parkinson’s disease: a longitudinal PET study
Tatsuhiro Terada, Tomoyasu Bunai, Takanori Hashizume, Takashi Matsudaira, Masamichi Yokokura, Hirotsugu Takashima, Takashi Konishi, Tomokazu Obi, Yasuomi Ouchi
Scientific Reports.2024;[Epub] CrossRef
Neuroinflammation and Immune Dysfunction in the Mechanisms of Development of Parkinson’s Disease
G. V. Idova, E. L. Alperina, S. Ya. Zhanaeva
Neuroscience and Behavioral Physiology.2023; 53(9): 1534. CrossRef
Vitamin D3 actions on astrocyte cells: A target for therapeutic strategy in Parkinson’s disease?
Erlânia Alves de Siqueira, Emanuel Paula Magalhães, Ramon Róseo Paula Pessoa Bezerra de Menezes, Tiago Lima Sampaio, Danya Bandeira Lima, Conceição da Silva Martins, Kelly Rose Tavares Neves, Gerly Anne de Castro Brito, Alice Maria Costa Martins, Glauce S
Neuroscience Letters.2023; 793: 136997. CrossRef
ASC specks exacerbate α‑synuclein pathology via amplifying NLRP3 inflammasome activities
Ran Zheng, Yiqun Yan, Shaobing Dai, Yang Ruan, Ying Chen, Chenjun Hu, Zhihao Lin, Naijia Xue, Zhe Song, Yi Liu, Baorong Zhang, Jiali Pu
Journal of Neuroinflammation.2023;[Epub] CrossRef
NLRP3 Inflammasome-Mediated Neuroinflammation and Related Mitochondrial Impairment in Parkinson’s Disease
Qiu-Qin Han, Weidong Le
Neuroscience Bulletin.2023; 39(5): 832. CrossRef
The Role of Ubiquitin–Proteasome System and Mitophagy in the Pathogenesis of Parkinson's Disease
Yu Liang, Guangshang Zhong, Mingxin Ren, Tingting Sun, Yangyang Li, Ming Ye, Caiyun Ma, Yu Guo, Changqing Liu
NeuroMolecular Medicine.2023; 25(4): 471. CrossRef
Anethole attenuates motor dysfunctions, striatal neuronal activity deficiency and blood brain barrier permeability by decreasing striatal α-synuclein and oxidative stress in rotenone-induced Parkinson’s disease of male rats
Sadegh Moradi Vastegani, Seyed Esmaeil Khoshnam, Samireh Ghafouri, Nima Bakhtiari, Yaghoob Farbood, Alireza Sarkaki, Wesley Lyeverton Correia Ribeiro
PLOS ONE.2023; 18(11): e0294612. CrossRef
A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable?
Andrea Spinaci, Catia Lambertucci, Michela Buccioni, Diego Dal Ben, Claudia Graiff, Maria Cristina Barbalace, Silvana Hrelia, Cristina Angeloni, Seyed Khosrow Tayebati, Massimo Ubaldi, Alessio Masi, Karl-Norbert Klotz, Rosaria Volpini, Gabriella Marucci
Molecules.2022; 27(8): 2386. CrossRef
Oligomeropathies, inflammation and prion protein binding
Gianluigi Forloni, Pietro La Vitola, Claudia Balducci
Frontiers in Neuroscience.2022;[Epub] CrossRef

Altered Gut Microbiome and Intestinal Pathology in Parkinson’s Disease: Han-Lin Chiang, Chin-Hsien Lin; J Mov Disord. 2019;12(2):67-83. Published online May 30, 2019; DOI: https://doi.org/10.14802/jmd.18067

15,766 View
749 Download
63 Web of Science
63 Crossref

Abstract PDF

Parkinson’s disease (PD) is a common neurodegenerative disorder arising from an interplay between genetic and environmental risk factors. Studies have suggested that the pathological hallmarks of intraneuronal α-synuclein aggregations may start from the olfactory bulb and the enteric nervous system of the gut and later propagate to the brain via the olfactory tract and the vagus nerve. This hypothesis correlates well with clinical symptoms, such as constipation, that may develop up to 20 years before the onset of PD motor symptoms. Recent interest in the gut–brain axis has led to vigorous research into the gastrointestinal pathology and gut microbiota changes in patients with PD. In this review, we provide current clinical and pathological evidence of gut involvement in PD by summarizing the changes in gut microbiota composition and gut inflammation associated with its pathogenesis.

Citations

Citations to this article as recorded by

Buty and the beast: the complex role of butyrate in Parkinson’s disease
Joshua D. Elford, Nanette Becht, Johan Garssen, Aletta D. Kraneveld, Paula Perez-Pardo
Frontiers in Pharmacology.2024;[Epub] CrossRef
Adipose tissue, systematic inflammation, and neurodegenerative diseases
AnaPaula de A. Boleti, PedroHenrique de O. Cardoso, BrenoEmanuel F. Frihling, PatríciaSouza e Silva, LuizFilipe R. N. de Moraes, Ludovico Migliolo
Neural Regeneration Research.2023; 18(1): 38. CrossRef
Parkinson's Disease: A Multisystem Disorder
Helena Nunes Costa, Ana Raquel Esteves, Nuno Empadinhas, Sandra Morais Cardoso
Neuroscience Bulletin.2023; 39(1): 113. CrossRef
Brain modulation by the gut microbiota: From disease to therapy
Sarmistha Mitra, Raju Dash, Amena Al Nishan, Sarmin Ummey Habiba, Il Soo Moon
Journal of Advanced Research.2023; 53: 153. CrossRef
Plasma Metabolic Analysis Reveals the Dysregulation of Short-Chain Fatty Acid Metabolism in Parkinson’s Disease
Ao Qi, Lulu Liu, Junjie Zhang, Simei Chen, Simin Xu, Yusen Chen, Lijiang Zhang, Chun Cai
Molecular Neurobiology.2023; 60(5): 2619. CrossRef
Fecal microbiota transplantation in Parkinson's disease—A randomized repeat-dose, placebo-controlled clinical pilot study
Herbert L. DuPont, Jessika Suescun, Zhi-Dong Jiang, Eric L. Brown, Heather T. Essigmann, Ashley S. Alexander, Andrew W. DuPont, Tehseen Iqbal, Netanya S. Utay, Michael Newmark, Mya C. Schiess
Frontiers in Neurology.2023;[Epub] CrossRef
Mesoporous silica nanoparticles: Their potential as drug delivery carriers and nanoscavengers in Alzheimer's and Parkinson's diseases
Mohamed S. Attia, Ahmed Yahya, Nada Abdel Monaem, Shereen A. Sabry
Saudi Pharmaceutical Journal.2023; 31(3): 417. CrossRef
GSDMD in peripheral myeloid cells regulates microglial immune training and neuroinflammation in Parkinson's disease
Bingwei Wang, Yan Ma, Sheng Li, Hang Yao, Mingna Gu, Ying Liu, You Xue, Jianhua Ding, Chunmei Ma, Shuo Yang, Gang Hu
Acta Pharmaceutica Sinica B.2023; 13(6): 2663. CrossRef
Gut-microbiome-brain axis: the crosstalk between the vagus nerve, alpha-synuclein and the brain in Parkinson’s disease
Júlio César Claudino dos Santos, Leandro Freitas Oliveira, Felipe Micelli Noleto, Camilla Teixeira Pinheiro Gusmão, Gerly Anne de Castro Brito, Glauce Socorro de Barros Viana
Neural Regeneration Research.2023; 18(12): 2611. CrossRef
Beyond the Microbiota: Understanding the Role of the Enteric Nervous System in Parkinson’s Disease from Mice to Human
Martina Montanari, Paola Imbriani, Paola Bonsi, Giuseppina Martella, Antonella Peppe
Biomedicines.2023; 11(6): 1560. CrossRef
Effects of gut microbiota on neurodegenerative diseases
Saima Khatoon, Nida Kalam, Summya Rashid, Gulnaz Bano
Frontiers in Aging Neuroscience.2023;[Epub] CrossRef
From-Toilet-to-Freezer: A Review on Requirements for an Automatic Protocol to Collect and Store Human Fecal Samples for Research Purposes
Frances Widjaja, Ivonne M. C. M. Rietjens
Biomedicines.2023; 11(10): 2658. CrossRef
Association between the risk and severity of Parkinson’s disease and plasma homocysteine, vitamin B12 and folate levels: a systematic review and meta-analysis
Yuxin Quan, Jisen Xu, Qing Xu, Zhiqing Guo, Ruwei Ou, Huifang Shang, Qianqian Wei
Frontiers in Aging Neuroscience.2023;[Epub] CrossRef
Oral pathogens exacerbate Parkinson’s disease by promoting Th1 cell infiltration in mice
Xue-Bing Bai, Shuo Xu, Lu-Jun Zhou, Xiao-Qian Meng, Yu-Lin Li, Yan-Lin Chen, Yi-Han Jiang, Wen-Zhen Lin, Bo-Yan Chen, Lin-Juan Du, Guo-Cai Tian, Yan Liu, Sheng-Zhong Duan, Ya-Qin Zhu
Microbiome.2023;[Epub] CrossRef
The intestinal luminal sources of α-synuclein: a gastroenterologist perspective
Aaron Lerner
Nutrition Reviews.2022; 80(2): 282. CrossRef
Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF‐α Pathway
Chin‐Hsien Lin, Han‐Yi Lin, En‐Pong Ho, Yi‐Ci Ke, Mei‐Fang Cheng, Chyng‐Yann Shiue, Chi‐Han Wu, Peng‐Hsiang Liao, Angela Yu‐Huey Hsu, Li‐An Chu, Ya‐Ding Liu, Ya‐Hui Lin, Yi‐Cheng Tai, Chia‐Tung Shun, Han‐Mo Chiu, Ming‐Shiang Wu
Movement Disorders.2022; 37(4): 745. CrossRef
Digesting recent findings: gut alpha-synuclein, microbiome changes in Parkinson’s disease
Ehraz Anis, Aoji Xie, Lena Brundin, Patrik Brundin
Trends in Endocrinology & Metabolism.2022; 33(2): 147. CrossRef
Animal models of brain-first and body-first Parkinson's disease
Nathalie Van Den Berge, Ayse Ulusoy
Neurobiology of Disease.2022; 163: 105599. CrossRef
Microbiome Changes in Humans with Parkinson’s Disease after Photobiomodulation Therapy: A Retrospective Study
Brian Bicknell, Ann Liebert, Craig S. McLachlan, Hosen Kiat
Journal of Personalized Medicine.2022; 12(1): 49. CrossRef
Passive Immunization in Alpha-Synuclein Preclinical Animal Models
Jonas Folke, Nelson Ferreira, Tomasz Brudek, Per Borghammer, Nathalie Van Den Berge
Biomolecules.2022; 12(2): 168. CrossRef
Dietary Succinoglycan Riclin Improves Glycemia Control in Mice with Type 2 Diabetes
Zhao Ding, Yang Zhao, Junhao Liu, Wenhao Ge, Xi Xu, Shiming Wang, Jianfa Zhang
Journal of Agricultural and Food Chemistry.2022; 70(6): 1819. CrossRef
Role of Microbiota-Gut-Brain Axis in Regulating Dopaminergic Signaling
Sevag Hamamah, Armin Aghazarian, Anthony Nazaryan, Andras Hajnal, Mihai Covasa
Biomedicines.2022; 10(2): 436. CrossRef
Distribution of α-Synuclein Aggregation in the Peripheral Tissues
Yan-yan Li, Tian-tian Zhou, Yi Zhang, Nai-Hong Chen, Yu-He Yuan
Neurochemical Research.2022; 47(12): 3627. CrossRef
Effects of Subdiaphragmatic Vagotomy in the MPTP-induced Neurotoxicity in the Striatum and Colon of Mice
Jiajing Shan, Youge Qu, Jiancheng Zhang, Li Ma, Kenji Hashimoto
Clinical Psychopharmacology and Neuroscience.2022; 20(2): 389. CrossRef
Alpha-Synuclein Strain Variability in Body-First and Brain-First Synucleinopathies
Mie Kristine Just, Hjalte Gram, Vasileios Theologidis, Poul Henning Jensen, K. Peter R. Nilsson, Mikael Lindgren, Karoline Knudsen, Per Borghammer, Nathalie Van Den Berge
Frontiers in Aging Neuroscience.2022;[Epub] CrossRef
Urolithins: potential biomarkers of gut dysbiosis and disease stage in Parkinson's patients
María Romo-Vaquero, Emiliano Fernández-Villalba, Ana-Luisa Gil-Martinez, Lorena Cuenca-Bermejo, Juan Carlos Espín, María Trinidad Herrero, María Victoria Selma
Food & Function.2022; 13(11): 6306. CrossRef
Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson’s disease
Hiroshi Nishiwaki, Mikako Ito, Tomonari Hamaguchi, Tetsuya Maeda, Kenichi Kashihara, Yoshio Tsuboi, Jun Ueyama, Takumi Yoshida, Hiroyuki Hanada, Ichiro Takeuchi, Masahisa Katsuno, Masaaki Hirayama, Kinji Ohno
npj Parkinson's Disease.2022;[Epub] CrossRef
Opicapone, a Novel Catechol-O-methyl Transferase Inhibitor, for Treatment of Parkinson’s Disease “Off” Episodes
Amnon A. Berger, Ariel Winnick, Jonathan Izygon, Binil M. Jacob, Jessica S. Kaye, Rachel J. Kaye, Elisa E. Neuchat, Adam M. Kaye, Edward S. Alpaugh, Elyse M. Cornett, Andrew H. Han, Alan D. Kaye
Health Psychology Research.2022;[Epub] CrossRef
The role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases
George Tsafaras, Veerle Baekelandt
Neurobiology of Disease.2022; 172: 105806. CrossRef
What Is the Prognostic Significance of Rapid Eye Movement Sleep Without Atonia in a Polysomnogram?
Frank Ralls, Lisa Cutchen, Madeleine M. Grigg-Damberger
Journal of Clinical Neurophysiology.2022; 39(5): 346. CrossRef
Lippia grata essential oil complexed with β-cyclodextrin ameliorates biochemical and behavioral deficits in an animal model of progressive parkinsonism
Jose Ivo A. Beserra-Filho, Amanda Maria-Macêdo, Suellen Silva-Martins, Ana Cláudia Custódio-Silva, Beatriz Soares-Silva, Sara Pereira Silva, Rafael Herling Lambertucci, Adriano Antunes de Souza Araújo, Angélica Maria Lucchese, Lucindo J. Quintans-Júnior,
Metabolic Brain Disease.2022; 37(7): 2331. CrossRef
Oral and gut dysbiosis leads to functional alterations in Parkinson’s disease
Sungyang Jo, Woorim Kang, Yun Su Hwang, Seung Hyun Lee, Kye Won Park, Mi Sun Kim, Hyunna Lee, Hyung Jeong Yoon, Yoo Kyoung Park, Mauricio Chalita, Je Hee Lee, Hojun Sung, Jae-Yun Lee, Jin-Woo Bae, Sun Ju Chung
npj Parkinson's Disease.2022;[Epub] CrossRef
Deciphering Intertwined Molecular Pathways Underlying Metabolic Syndrome Leading to Parkinson’s Disease
Ritu Soni, Jigna Shah
ACS Chemical Neuroscience.2022; 13(15): 2240. CrossRef
Therapeutic potential of short-chain fatty acid production by gut microbiota in neurodegenerative disorders
Sarika Yadav, Ashish Dwivedi, Anurag Tripathi, Amit Kumar Tripathi
Nutrition Research.2022; 106: 72. CrossRef
Development of neurodegenerative disorders and the role of gut
Woong-Woo Lee
Journal of Geriatric Neurology.2022; 1(2): 53. CrossRef
What Are the Key Gut Microbiota Involved in Neurological Diseases? A Systematic Review
Bruno Bonnechère, Najaf Amin, Cornelia van Duijn
International Journal of Molecular Sciences.2022; 23(22): 13665. CrossRef
Gut microbiota in dementia with Lewy bodies
Hiroshi Nishiwaki, Jun Ueyama, Kenichi Kashihara, Mikako Ito, Tomonari Hamaguchi, Tetsuya Maeda, Yoshio Tsuboi, Masahisa Katsuno, Masaaki Hirayama, Kinji Ohno
npj Parkinson's Disease.2022;[Epub] CrossRef
Gut dysbiosis in stroke and its implications on Alzheimer’s disease‐like cognitive dysfunction
Justin Cho, You Jeong Park, Bella Gonzales‐Portillo, Madeline Saft, Blaise Cozene, Nadia Sadanandan, Cesar V. Borlongan
CNS Neuroscience & Therapeutics.2021; 27(5): 505. CrossRef
Plasma Lipopolysaccharide-Binding Protein Reflects Risk and Progression of Parkinson’s Disease
Szu-Ju Chen, Yu-Chiao Chi, Chang-Han Ho, Wei-Shiung Yang, Chin-Hsien Lin
Journal of Parkinson's Disease.2021; 11(3): 1129. CrossRef
Parkinson's disease and the gut: Models of an emerging relationship
Adam J. Bindas, Subhash Kulkarni, Ryan A. Koppes, Abigail N. Koppes
Acta Biomaterialia.2021; 132: 325. CrossRef
Ageing promotes pathological alpha-synuclein propagation and autonomic dysfunction in wild-type rats
Nathalie Van Den Berge, Nelson Ferreira, Trine Werenberg Mikkelsen, Aage Kristian Olsen Alstrup, Gültekin Tamgüney, Páll Karlsson, Astrid Juhl Terkelsen, Jens Randel Nyengaard, Poul Henning Jensen, Per Borghammer
Brain.2021; 144(6): 1853. CrossRef
Desulfovibrio Bacteria Are Associated With Parkinson’s Disease
Kari E. Murros, Vy A. Huynh, Timo M. Takala, Per E. J. Saris
Frontiers in Cellular and Infection Microbiology.2021;[Epub] CrossRef
“Janus-Faced” α-Synuclein: Role in Parkinson’s Disease
Bipul Ray, Arehally M. Mahalakshmi, Sunanda Tuladhar, Abid Bhat, Asha Srinivasan, Christophe Pellegrino, Anbarasu Kannan, Srinivasa Rao Bolla, Saravana Babu Chidambaram, Meena Kishore Sakharkar
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson's disease
Jonas Ghyselinck, Lynn Verstrepen, Frédéric Moens, Pieter Van Den Abbeele, Arnout Bruggeman, Jawal Said, Barry Smith, Lynne Ann Barker, Caroline Jordan, Valentina Leta, K. Ray Chaudhuri, Abdul W. Basit, Simon Gaisford
International Journal of Pharmaceutics: X.2021; 3: 100087. CrossRef
The Role of The Gut Microbiome in Parkinson’s Disease
Amy Gallop, James Weagley, Saif-ur-Rahman Paracha, George Grossberg
Journal of Geriatric Psychiatry and Neurology.2021; 34(4): 253. CrossRef
The Baseline Structure of the Enteric Nervous System and Its Role in Parkinson’s Disease
Gianfranco Natale, Larisa Ryskalin, Gabriele Morucci, Gloria Lazzeri, Alessandro Frati, Francesco Fornai
Life.2021; 11(8): 732. CrossRef
Regulation of neurotoxicity in the striatum and colon of MPTP-induced Parkinson’s disease mice by gut microbiome
Jiajing Shan, Youge Qu, Siming Wang, Yan Wei, Lijia Chang, Li Ma, Kenji Hashimoto
Brain Research Bulletin.2021; 177: 103. CrossRef
Cholecystectomy and subsequent risk of Parkinson’s disease: a nationwide retrospective cohort study
Ryul Kim, Jee-Young Lee, Sanghyun Park, Kyungdo Han, Cheol Min Shin
npj Parkinson's Disease.2021;[Epub] CrossRef
Benefits of Helicobacter pylori Eradication on Extragastric Diseases
Tae Jun Kim, Hyuk Lee
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2021; 21(4): 275. CrossRef
Higher cerebrospinal fluid to plasma ratio of p-cresol sulfate and indoxyl sulfate in patients with Parkinson’s disease
Bartłomiej Sankowski, Karolina Księżarczyk, Emilia Raćkowska, Stanisław Szlufik, Dariusz Koziorowski, Joanna Giebułtowicz
Clinica Chimica Acta.2020; 501: 165. CrossRef
The microbiome-gut-brain axis in acute and chronic brain diseases
Corinne Benakis, Camille Martin-Gallausiaux, Jean-Pierre Trezzi, Philip Melton, Arthur Liesz, Paul Wilmes
Current Opinion in Neurobiology.2020; 61: 1. CrossRef
The progress of gut microbiome research related to brain disorders
Sibo Zhu, Yanfeng Jiang, Kelin Xu, Mei Cui, Weimin Ye, Genming Zhao, Li Jin, Xingdong Chen
Journal of Neuroinflammation.2020;[Epub] CrossRef
Minireview on the Relations between Gut Microflora and Parkinson’s Disease: Further Biochemical (Oxidative Stress), Inflammatory, and Neurological Particularities
Ovidiu-Dumitru Ilie, Alin Ciobica, Jack McKenna, Bogdan Doroftei, Ioannis Mavroudis, Tuane B. Sampaio
Oxidative Medicine and Cellular Longevity.2020; 2020: 1. CrossRef
Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications?
Carolina Pellegrini, Luca Antonioli, Vincenzo Calderone, Rocchina Colucci, Matteo Fornai, Corrado Blandizzi
Progress in Neurobiology.2020; 191: 101806. CrossRef
Meta‐Analysis of Gut Dysbiosis in Parkinson's Disease
Hiroshi Nishiwaki, Mikako Ito, Tomohiro Ishida, Tomonari Hamaguchi, Tetsuya Maeda, Kenichi Kashihara, Yoshio Tsuboi, Jun Ueyama, Teppei Shimamura, Hiroshi Mori, Ken Kurokawa, Masahisa Katsuno, Masaaki Hirayama, Kinji Ohno
Movement Disorders.2020; 35(9): 1626. CrossRef
In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons
Maria Fouka, Panagiota Mavroeidi, Grigoria Tsaka, Maria Xilouri
Frontiers in Cell and Developmental Biology.2020;[Epub] CrossRef
Role of Carbon Monoxide in Host–Gut Microbiome Communication
Christopher P. Hopper, Ladie Kimberly De La Cruz, Kristin V. Lyles, Lauren K. Wareham, Jack A. Gilbert, Zehava Eichenbaum, Marcin Magierowski, Robert K. Poole, Jakob Wollborn, Binghe Wang
Chemical Reviews.2020; 120(24): 13273. CrossRef
Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson’s Disease
Chrysoula Marogianni, Maria Sokratous, Efthimios Dardiotis, Georgios M. Hadjigeorgiou, Dimitrios Bogdanos, Georgia Xiromerisiou
International Journal of Molecular Sciences.2020; 21(22): 8421. CrossRef
Niacin and Butyrate: Nutraceuticals Targeting Dysbiosis and Intestinal Permeability in Parkinson’s Disease
Tennekoon B. Karunaratne, Chijioke Okereke, Marissa Seamon, Sharad Purohit, Chandramohan Wakade, Amol Sharma
Nutrients.2020; 13(1): 28. CrossRef
Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson’s Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder
Hiroshi Nishiwaki, Tomonari Hamaguchi, Mikako Ito, Tomohiro Ishida, Tetsuya Maeda, Kenichi Kashihara, Yoshio Tsuboi, Jun Ueyama, Teppei Shimamura, Hiroshi Mori, Ken Kurokawa, Masahisa Katsuno, Masaaki Hirayama, Kinji Ohno, Chaysavanh Manichanh
mSystems.2020;[Epub] CrossRef
The Intestinal Barrier in Parkinson’s Disease: Current State of Knowledge
Sven C. D. van IJzendoorn, Pascal Derkinderen, Teus van Laar
Journal of Parkinson's Disease.2019; 9(s2): S323. CrossRef
Medical management, prevention and mitigation of environmental risks factors in Neurology
J. Reis, G.C. Román, M. Giroud, V.S. Palmer, P.S. Spencer
Revue Neurologique.2019; 175(10): 698. CrossRef
Antibiotic-induced microbiome depletion protects against MPTP-induced dopaminergic neurotoxicity in the brain
Yaoyu Pu, Lijia Chang, Youge Qu, Siming Wang, Kai Zhang, Kenji Hashimoto
Aging.2019; 11(17): 6915. CrossRef

First
Prev
Page of 1
Next
Last

Search